TABLE 2.
Clinicopathologic Factors Associated With Recurrence in HP-Negative MALT Lymphomaa
| Variable | Odds ratio (95% CI) | P value |
|---|---|---|
| Age, y | ||
| <65 (reference) | ||
| ≥65 | 1.40 (0.34-4.95) | .74 |
| Sex | ||
| Male (reference) | ||
| Female | 1.82 (0.52-6.35) | .49 |
| Etiologic factors | ||
| None identified (reference) | ||
| Autoimmune disease | 0.63 (0.11-4.08) | .62 |
| Symptoms present | ||
| No (reference) | ||
| Yes | 0.67 (0.03-14.12) | .78 |
| Endoscopic findings | ||
| No visible lesion (reference) | ||
| Visible lesion | 0.64 (0.14-2.89) | .60 |
| Mass lesion | 5.02 (0.87-24.96) | .08 |
| Gastric location | ||
| Proximal (reference) | ||
| Distal involvement | 0.23 (0.04-1.20) | .10 |
| Immunophenotype | ||
| CD43 negative (reference) | ||
| CD43 positive | 0.86 (0.15-4.85) | .88 |
| CD5 negative (reference) | ||
| CD5 positive | 5.25 (0.64-72.16) | .15 |
| Histologic gastritis | ||
| None (reference) | ||
| Mild or severe | 0.28 (0.02-2.67) | .28 |
| B-cell gene rearrangement | ||
| Negative (reference) | ||
| Positive | 0.19 (0.01-1.46) | .13 |
| Therapy | ||
| Antibiotic | 4.44 (0.45-67.00) | .22 |
| Radiation | 0.23 (0.06-1.02) | .06 |
| Rituximab, single agent | 2.43 (0.56-10.46) | .28 |
| Chemotherapy | 1.33 (0.21-7.45) | .77 |
aUnivariate analysis using Fisher exact test.